DOCSLIB.ORG

Rules of Department of Health and Senior Services Division 30—Division of Regulation and Licensure Chapter 1—Controlled Substances

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Rules of Department of Health and Senior Services Division 30—Division of Regulation and Licensure Chapter 1—Controlled Substances Rules of Department of Health and Senior Services Division 30—Division of Regulation and Licensure Chapter 1—Controlled Substances Title Page 19 CSR 30-1.002 Schedules of Controlled Substances .........................................................3 19 CSR 30-1.004 List of Excepted Substances ..................................................................8 19 CSR 30-1.006 List of Exempt Anabolic Steroid Products .................................................8 19 CSR 30-1.008 List of Excluded Veterinary Anabolic Steroid Implant Products .......................9 19 CSR 30-1.010 Schedules of Controlled Substances (Rescinded November 30, 2000) ................9 19 CSR 30-1.011 Definitions......................................................................................10 19 CSR 30-1.013 Miscellaneous Fees ...........................................................................11 19 CSR 30-1.015 Registrations and Fees........................................................................11 19 CSR 30-1.017 Registration Process ..........................................................................11 19 CSR 30-1.019 Registration Location.........................................................................14 19 CSR 30-1.020 List of Excepted Substances (Rescinded November 30, 2000)........................14 19 CSR 30-1.023 Registration Changes .........................................................................14 19 CSR 30-1.025 List of Exempt Anabolic Steroid Products (Rescinded November 30, 2000).......15 19 CSR 30-1.026 Separate Registrations ........................................................................15 19 CSR 30-1.027 Investigative and Administrative Procedures .............................................15 19 CSR 30-1.030 Requirements for Controlled Substances Registration (Rescinded November 30, 2000) ..........................................................16 19 CSR 30-1.031 Physical Security Requirements.............................................................16 19 CSR 30-1.032 Security for Nonpractitioners ...............................................................16 19 CSR 30-1.033 Hearing Procedures on Controlled Substances Registration (Rescinded November 30, 2000) ..........................................................17 ROBIN CARNAHAN (10/31/11) CODE OF STATE REGULATIONS 1 Secretary of State 19 CSR 30-1.034 Security for Practitioners ....................................................................17 19 CSR 30-1.035 Requirements for Prescribing, Dispensing and Administering Controlled Substances (Rescinded November 30, 2000) ...............................18 19 CSR 30-1.036 Disposing of Unwanted Controlled Substances (Rescinded November 30, 2000) ..........................................................18 19 CSR 30-1.040 Dispensing and Distribution of Controlled Substances in Certain Situations (Rescinded July 30, 2003) ..................................................................18 19 CSR 30-1.041 Records Requirements........................................................................18 19 CSR 30-1.042 Inventory Requirements ......................................................................18 19 CSR 30-1.044 Continuing Records General Requirements...............................................20 19 CSR 30-1.046 Records for Manufacturers, Distributors, Importers and Exporters ..................20 19 CSR 30-1.048 Records for Practitioners and Researchers................................................21 19 CSR 30-1.050 Records for Chemical Analysts .............................................................22 19 CSR 30-1.052 Records for Long-Term Care Facilities (LTCF)..........................................22 19 CSR 30-1.060 Determining Lawful Prescribing, Dispensing and Administering of Controlled Substances....................................................................23 19 CSR 30-1.062 Transmission of Prescriptions...............................................................23 19 CSR 30-1.064 Partial Filling of Schedule II Prescriptions ...............................................23 19 CSR 30-1.066 Dispensing by Individual Practitioners ....................................................24 19 CSR 30-1.068 Administering In Emergency Rooms.......................................................24 19 CSR 30-1.070 Emergency Dispensing of Schedule II Substances.......................................24 19 CSR 30-1.072 Dispensing of Schedule V Substances .....................................................25 19 CSR 30-1.074 Dispensing Without a Prescription .........................................................25 19 CSR 30-1.076 Emergency Distribution by a Pharmacy ...................................................27 19 CSR 30-1.078 Disposing of Unwanted Controlled Substances ..........................................27 2 CODE OF STATE REGULATIONS (10/31/11) ROBIN CARNAHAN Secretary of State Chapter 1—Controlled Substances 19 CSR 30-1 Title 19—DEPARTMENT OF K. Beta-hydroxyfentanyl (N-(1-(2- YY. Propiram 9649 HEALTH AND SENIOR SERVICES hydroxy-2-phenethyl)-4-piperi- ZZ. Racemoramide 9645 Division 30—Division of dinyl)-N-phenylpropan- AAA. Thiofentanyl Regulation and Licensure amide) 9830 (N-phenyl-N-(1-(2- Chapter 1—Controlled Substances L. Beta-hydroxy-3-methylfentanyl thienyl)ethyl-4-piperidinyl)- (other name: N-(1-(2-hydroxy- propanamide 9835 19 CSR 30-1.002 Schedules of Controlled 2-phenethyl)-3-methyl-4- BBB. Tilidine 9750 Substances piperidinyl)-N-phenylpropan- CCC. Trimeperidine 9646 amide) 9831 2. Opium derivatives. Unless specifical- PURPOSE: Chapter 195, RSMo states in sec- M. Betameprodine 9608 ly excepted or unless listed in another sched- tion 195.230, RSMo that the Department of N. Betamethadol 9609 ule, any of the following opium derivatives, Health shall prepare a list of all drugs falling O. Betaprodine 9611 its salts, isomers and salts of isomers when- within the purview of controlled substances. P. Clonitazene 9612 ever the existence of such salts, isomers and Upon preparation, a copy of the list shall be Q. Dextromoramide 9613 salts of isomers is possible within the specif- filed in the Office of the Secretary of State. It R. Diampromide 9615 ic chemical designation: also requires, in section 195.017.11, RSMo, S. Diethylthiambutene 9616 A. Acetorphine 9319 the Department of Health to revise and repub- T. Difenoxin 9168 B. Acetyldihydrocodeine 9051 lish the schedules semiannually for two years U. Dimenoxadol 9617 C. Benzylmorphine 9052 from September 28, 1971, and annually after V. Dimepheptanol 9618 D. Codeine methylbromide 9070 that. W. Dimethylthiambutene 9619 E. Codeine-N-Oxide 9053 X. Dioxaphetyl butyrate 9621 F. Cyprenorphine 9054 (1) Schedules of Controlled Substances. Y. Dipipanone 9622 G. Desomorphine 9055 (A) Schedule I shall consist of the drugs Z. Ethylmethylthiambutene 9623 H. Dihydromorphine 9145 and other substances, by whatever official AA. Etonitazene 9624 I. Drotebanol 9335 name, common or usual name, chemical BB. Etoxeridine 9625 J. Etorphine (except hydro- name or brand name designated, listed in this CC. Furethidine 9626 chloride salt) 9056 DD. Hydroxypethidine 9627 section. Each drug or substance has been K. Heroin 9200 EE. Ketobemidone 9628 assigned the Drug Enforcement Administra- L. Hydromorphinol 9301 FF. Levomoramide 9629 tion (DEA) Controlled Substances Code M. Methyldesorphine 9302 GG. Levophenacylmorphan 9631 Number set forth opposite it. N. Methyldihydromorphine 9304 HH. 3-Methylfentanyl (N-(3-methyl- 1. Opiates. Unless specifically excepted O. Morphine methylbromide 9305 1-(2-phenylethyl)-4- or unless listed in another schedule, any of P. Morphine methylsulfonate 9306 piperidyl)-N-phenylproan- the following opiates, including their isomers, Q. Morphine-N-Oxide 9307 amide), its optical and esters, ethers, salts and salts of isomers, R. Myrophine 9308 geometric isomers, salts and esters and ethers, whenever the existence of S. Nicocodeine 9309 salts of isomers 9813 such isomers, esters, ethers and salts is pos- II. 3-Methylthiofentanyl (N-((3- T. Nicomorphine 9312 sible within the specific chemical designa- methyl-1-(2-thienyl) U. Normorphine 9313 tion: ethyl-4-piperidinyl)-N- V. Pholcodeine 9314 A. Acetyl-alpha-methylfentanyl (N- phenylpropanamide) 9833 W. Thebacon 9315 (1-(1-methyl-2-phenethyl)- JJ. Morpheridine 9632 3. Hallucinogenic substances. Unless 4-piperidinyl)-N-phenylace- KK. MPPP (1-methyl-4-phenyl- specifically excepted or unless listed in tamide) 9815 4-propionoxypiperidine) 9661 another schedule, any material, compound, B. Acetylmethadol 9601 LL. Noracymethadol 9633 mixture or preparation, which contains any C. Allylprodine 9602 MM. Norlevorphanol 9634 quantity of the following hallucinogenic sub- D. Alphacetylmethadol (except levo- NN. Normethadone 9635 stances or which contains any of its salts, iso- alphacetylmethadol also known OO. Norpipanone 9636 mers and salts of isomers whenever the exis- as levo-alpha-acetylmethadol levo- PP. Para-fluorofentanyl tence of such salts, isomers and salts of thadyl acetate or LAAM) 9603 (N-(4-fluorophenyl)- isomers is possible within the specific chem- E. Alphameprodine 9604 N-(1-(2-phenethyl)-4- ical designation (For purposes of paragraph F. Alphamethadol 9605 piperidinyl) propana- (1)(A)3. of this rule only, the term isomer G. Alpha-methylfentanyl (N-1- mide 9812 includes the optical, position and geometric (alphamethyl-beta-phenyl) ethyl- QQ. PEPAP (1-(-2-phenethyl)-4- isomers.): 4-piperidyl) propionanilide; 1-(1- phenyl-4-acetoxypi-
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 6,284,263 B1 Place (45) Date of Patent: Sep
    USOO6284263B1 (12) United States Patent (10) Patent No.: US 6,284,263 B1 Place (45) Date of Patent: Sep. 4, 2001 (54) BUCCAL DRUG ADMINISTRATION IN THE 4,755,386 7/1988 Hsiao et al. TREATMENT OF FEMALE SEXUAL 4,764,378 8/1988 Keith et al.. DYSFUNCTION 4,877,774 10/1989 Pitha et al.. 5,135,752 8/1992 Snipes. 5,190,967 3/1993 Riley. (76) Inventor: Virgil A. Place, P.O. Box 44555-10 5,346,701 9/1994 Heiber et al. Ala Kahua, Kawaihae, HI (US) 96743 5,516,523 5/1996 Heiber et al. 5,543,154 8/1996 Rork et al. ........................ 424/133.1 (*) Notice: Subject to any disclaimer, the term of this 5,639,743 6/1997 Kaswan et al. patent is extended or adjusted under 35 6,180,682 1/2001 Place. U.S.C. 154(b) by 0 days. * cited by examiner (21) Appl. No.: 09/626,772 Primary Examiner Thurman K. Page ASSistant Examiner-Rachel M. Bennett (22) Filed: Jul. 27, 2000 (74) Attorney, Agent, or Firm-Dianne E. Reed; Reed & Related U.S. Application Data ASSciates (62) Division of application No. 09/237,713, filed on Jan. 26, (57) ABSTRACT 1999, now Pat. No. 6,117,446. A buccal dosage unit is provided for administering a com (51) Int. Cl. ............................. A61F 13/02; A61 K9/20; bination of Steroidal active agents to a female individual. A61K 47/30 The novel buccal drug delivery Systems may be used in (52) U.S. Cl. .......................... 424/435; 424/434; 424/464; female hormone replacement therapy, in female 514/772.3 contraception, to treat female Sexual dysfunction, and to treat or prevent a variety of conditions and disorders which (58) Field of Search ....................................
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Medication Use for the Risk Reduction of Primary Breast Cancer in Women: a Systematic Review for the U.S
    Evidence Synthesis Number 180 Medication Use for the Risk Reduction of Primary Breast Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. HHSA-290-2015-00009-I, Task Order No. 7 Prepared by: Pacific Northwest Evidence-Based Practice Center Oregon Health & Science University Mail Code: BICC 3181 SW Sam Jackson Park Road Portland, OR 97239 www.ohsu.edu/epc Investigators: Heidi D. Nelson, MD, MPH Rongwei Fu, PhD Bernadette Zakher, MBBS Marian McDonagh, PharmD Miranda Pappas, MA L.B. Miller, BA Lucy Stillman, BS AHRQ Publication No. 19-05249-EF-1 January 2019 This report is based on research conducted by the Pacific Northwest Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (HHSA-290-2015-00009-I, Task Order No. 7). The findings and conclusions in this document are those of the authors, who are responsible for its contents, and do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment.
    [Show full text]
  • Controlled Substances Listed in This Section from Schedule VI
    Page 1 of 15 ARTICLE II Schedule I (a) Schedule I shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it. (b) Opiates: (Narcotic Drugs) Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, salts is possible within the specific chemical designation (for purposes of paragraph (b)(34) only, the term isomer includes the optical and geometric isomers): (1) Acetyl-alpha-methylfentanyl(N-[1-[1-methyl-2- phenethyl)-4-piperidinyl]-N-phenylacetamide) ----- 9815-(2-86) (2) Acetylmethadol ----------------------------------- 9601* (3) Allylprodine ------------------------------------- 9602* (4) Alphacetylmethadol (except Levo-alphacetylmethadol (LAAM)------------------------------- 9603* (5) Alphameprodine ----------------------------------- 9604* (6) Alphamethadol ------------------------------------ 9605* (7) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl) ethyl-4-piperidyl]propronanilide; 1-(1-methyl- 2-phenylethyl)-4(N-propanilido)piperidine) ------- 9814-(6-82) (8) Alpha-methylthiofentanyl(N-[1-methyl-2-(2thienyl) ethyl-4-piperidinyl]-N-phenylpropanamide) -------- 9832-(2-86) (9) Benzethidine ------------------------------------- 9606* (10)
    [Show full text]
  • TESLAC (Testolactone Tablets, USP) Is Available for Oral Administration As Tablets Providing 50 Mg Testolactone Per Tablet
    ® TESLAC Rx only (testolactone tablets, USP) DESCRIPTION TESLAC (testolactone tablets, USP) is available for oral administration as tablets providing 50 mg testolactone per tablet. Testolactone is a synthetic antineoplastic agent that is structurally distinct from the androgen steroid nucleus in possessing a six-membered lactone ring in place of the usual five-membered carbocyclic D-ring. Testolactone is chemically designated as 13- hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic acid δ-lactone. Graphic formula: C19H24O3 MW300.40 CAS-968-93-4 Inactive ingredients: calcium stearate, cornstarch, gelatin, and lactose. Testolactone is a white, odorless, crystalline solid, soluble in ethanol and slightly soluble in water. CLINICAL PHARMACOLOGY Although the precise mechanism by which testolactone produces its clinical antineoplastic effects has not been established, its principal action is reported to be inhibition of steroid aromatase activity and consequent reduction in estrone synthesis from adrenal androstenedione, the major source of estrogen in postmenopausal women. Based on in vitro studies, the aromatase inhibition may be noncompetitive and irreversible. This phenomenon may account for the persistence of testolactone’s effect on estrogen synthesis after drug withdrawal. 1 Despite some similarity to testosterone, testolactone has no in vivo androgenic effect. No other hormonal effects have been reported in clinical studies in patients receiving testolactone. In one study, testolactone administered orally (1000 mg/day) was reported to increase renal tubular reabsorption of calcium but to have no effect on serum calcium concentration. The mechanism of the hypocalciuric effect is unknown. No clinical effects in humans of testolactone on adrenal function have been reported; however, one study noted an increase in urinary excretion of 17-ketosteroids in most of the patients treated with 150 mg/day orally.
    [Show full text]
  • AHFS Therapeutic
    AHFS Therapeutic AHFS Therapeutic Class Description HICL HICL Description Program Edit Criteria 1 Edit Criteria 2 Edit Criteria 3 Edit Criteria 4 Edit Criteria 5 Class 240408 CARDIOTONIC AGENTS 000004 DIGOXIN PACE MAX DAILY UNITS : 0.667000 240408 CARDIOTONIC AGENTS 000004 DIGOXIN PACE MAX DAILY UNITS : 0.750000 240408 CARDIOTONIC AGENTS 000004 DIGOXIN PACE MAX DAILY UNITS : 1.500000 240408 CARDIOTONIC AGENTS 000004 DIGOXIN PACE MAX DAILY UNITS : 2.000000 240408 CARDIOTONIC AGENTS 000004 DIGOXIN PACE MAX DAILY UNITS : 2.500000 240408 CARDIOTONIC AGENTS 000004 DIGOXIN PACE MAX DAILY UNITS : 3.000000 240408 CARDIOTONIC AGENTS 000004 DIGOXIN PACE MAX DAILY UNITS : 3.750000 240408 CARDIOTONIC AGENTS 000004 DIGOXIN PACE MAX DAILY UNITS : 6.000000 240408 CARDIOTONIC AGENTS 000004 DIGOXIN PACE MAX DAILY UNITS : 7.500000 240408 CARDIOTONIC AGENTS 000004 DIGOXIN PACE Medical Exception Required 282032 RESPIRATORY AND CNS STIMULANTS 000007 CAFFEINE/DEXTROSE PACE Cannnot co‐administer inhaled Insulin and Asthma/COPD/Smoking Cessation agents 282032 RESPIRATORY AND CNS STIMULANTS 000008 CAFFEINE/MULTIVITAMIN PACE Cannnot co‐administer inhaled Insulin and Asthma/COPD/Smoking Cessation agents 282032 RESPIRATORY AND CNS STIMULANTS 000009 CAFFEINE/ETHYL ALCOHOL PACE Cannnot co‐administer inhaled Insulin and Asthma/COPD/Smoking Cessation agents 282032 RESPIRATORY AND CNS STIMULANTS 000010 CAFFEINE/SODIUM BENZOATE PACE Cannnot co‐administer inhaled Insulin and Asthma/COPD/Smoking Cessation agents 282032 RESPIRATORY AND CNS STIMULANTS 000011 CAFFEINE CITRATE
    [Show full text]
  • Testotoxicosis: Gonadotrophin - Independent Male Sexual Precocity
    Postgrad Med J: first published as 10.1136/pgmj.68.797.225 on 1 March 1992. Downloaded from Postgrad Med J (1992) 68, 225 - 228 i) The Fellowship of Postgraduate Medicine, 1992 Testotoxicosis: gonadotrophin - independent male sexual precocity ArifAbdul Aziz, S.M.W. Jafri and Naeem Ul Haque Department ofMedicine, The Aga Khan University Hospital, Stadium Road, PO Box 3500, Karachi 74800, Pakistan Summary: In this era of rapidly developing investigational tools and pharmacology, the patho- physiology of precocious puberty is becoming well defined. What was previously thought to be a form of gonadotrophin releasing hormone (GNRH)-dependent central precocious puberty is now classified as GNRH-independent familial testotoxicosis. We present two such cases and review the clinical features, pathophysiology and treatment of testotoxicosis. Introduction Sexual precocity is defined as the appearance of medications during pregnancy. He was noted to physical signs of puberty before 8 years of age in have a rather large penis at 6 weeks of age when he females or 9 years of age in males. The clinical was circumcised. At the age of 6-9 months pubic disorders that induce sexual precocity can be hairs were noted. At age 2 years his height was by copyright. classified as gonadotrophin releasing hormone 99.7 cm and weight was approximately 15 kg both (GNRH) dependent or GNRH independent.' being above 97th percentile. He had a bone age of Male sexual precocity first described as a form of 6.4 years. He had stage IV genital development, central precocious puberty has recently been char- Stage IV pubic hair and testicular volume of 8 ml acterized as a familial intratesticular disorder.2'3 (Figures 1 and 2).
    [Show full text]
  • Lääkealan Turvallisuus- Ja Kehittämiskeskuksen Päätös
    Lääkealan turvallisuus- ja kehittämiskeskuksen päätös N:o xxxx lääkeluettelosta Annettu Helsingissä xx päivänä maaliskuuta 2016 ————— Lääkealan turvallisuus- ja kehittämiskeskus on 10 päivänä huhtikuuta 1987 annetun lääke- lain (395/1987) 83 §:n nojalla päättänyt vahvistaa seuraavan lääkeluettelon: 1 § Lääkeaineet ovat valmisteessa suolamuodossa Luettelon tarkoitus teknisen käsiteltävyyden vuoksi. Lääkeaine ja sen suolamuoto ovat biologisesti samanarvoisia. Tämä päätös sisältää luettelon Suomessa lääk- Liitteen 1 A aineet ovat lääkeaineanalogeja ja keellisessä käytössä olevista aineista ja rohdoksis- prohormoneja. Kaikki liitteen 1 A aineet rinnaste- ta. Lääkeluettelo laaditaan ottaen huomioon lää- taan aina vaikutuksen perusteella ainoastaan lää- kelain 3 ja 5 §:n säännökset. kemääräyksellä toimitettaviin lääkkeisiin. Lääkkeellä tarkoitetaan valmistetta tai ainetta, jonka tarkoituksena on sisäisesti tai ulkoisesti 2 § käytettynä parantaa, lievittää tai ehkäistä sairautta Lääkkeitä ovat tai sen oireita ihmisessä tai eläimessä. Lääkkeeksi 1) tämän päätöksen liitteessä 1 luetellut aineet, katsotaan myös sisäisesti tai ulkoisesti käytettävä niiden suolat ja esterit; aine tai aineiden yhdistelmä, jota voidaan käyttää 2) rikoslain 44 luvun 16 §:n 1 momentissa tar- ihmisen tai eläimen elintoimintojen palauttami- koitetuista dopingaineista annetussa valtioneuvos- seksi, korjaamiseksi tai muuttamiseksi farmako- ton asetuksessa kulloinkin luetellut dopingaineet; logisen, immunologisen tai metabolisen vaikutuk- ja sen avulla taikka terveydentilan
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Aromatase Inhibitors in the Treatment of Oligozoospermic Or Azoospermic Men: a Systematic Review of Randomized Controlled Trials
    JBRA Assisted Reproduction 2016;20(2):82-88 doi: 10.5935/1518-0557.20160019 Review Article Aromatase inhibitors in the treatment of oligozoospermic or azoospermic men: a systematic review of randomized controlled trials Mariana A. Ribeiro1, Luís F. O. Gameiro2, Wellerson R. Scarano1, Christine Briton-Jones3, Anil Kapoor4,5, Mauro B. Rosa6, Regina El Dib5,7 1Department of Morphology, Institute of Biosciences, Sao Paulo State University, UNESP, Botucatu, SP, Brazil 2Physiotherapy Service School of Medicine, Sao Paulo State University, UNESP, Botucatu, SP, Brazil 3Reproductive Medicine Partners of New York, New York, NY, USA 4Genito-Urinary Oncology Program, Juravinski Cancer Centre, Hamilton, ON, Canada 5McMaster Institute of Urology, at St. Joseph’s Healthcare, Hamilton, ON, Canada 6Hospital do Coração (HCOR), Sao Paulo,SP, Brazil 7Department of Anesthesiology, Faculdade de Medicina de Botucatu (FMB), Sao Paulo State University, UNESP, Botucatu, SP, Brazil ABSTRACT endogenous testosterone production without the asso- The aim of this study as to analyze published evidence ciated increase in circulating estrogens seen with es- regarding the effectiveness of aromatase inhibitor therapy trogen receptor modulators (Pavlovich et al., 2001). on improving spermatogenesis in infertile men. We carried AIs are classified as either steroidal or nonsteroidal. Ste- out a systematic review of randomized controlled trials. roidal inhibitors (such as testolactone, formestane, and The date of the most recent search was October 4, 2015. exemestane) competitively inhibit aromatase by mimick- Two authors independently selected relevant clinical trials, ing androstenedione, causing irreversible enzyme inhibi- assessing their methodological quality and extracting data. tion. Letrozole and anastrozole are nonsteroidal inhibitors Three studies were included in this review with a total of that cause reversible enzyme inhibition.
    [Show full text]
  • SENATE BILL No. 1237 No
    SENATE BILL No. 1237 SENATE BILL No. 1237 March 26, 2008, Introduced by Senators SWITALSKI, GLEASON, ANDERSON, KAHN, PAPPAGEORGE, BIRKHOLZ and JACOBS and referred to the Committee on Health Policy. A bill to amend 1978 PA 368, entitled "Public health code," by amending section 7216 (MCL 333.7216), as amended by 1999 PA 42. THE PEOPLE OF THE STATE OF MICHIGAN ENACT: 1 Sec. 7216. (1) The following controlled substances are 2 included in schedule 3: 3 (a) Unless listed in another schedule, any material, 4 compound, mixture, or preparation containing any quantity of the 5 following substances having a potential for abuse associated with 6 a stimulant effect on the central nervous system, including their 7 salts, isomers, including optical, position, or geometric 8 isomers, and salts of the isomers if the existence of the salts, 9 isomers, and salts of isomers is possible within the specific SENATE BILL No. 1237 06180'07 KKR 2 1 chemical designation: 2 Benzphetamine Mediatric tabs 3 Chlorphentermine Mediatric liquid 4 Clortermine Phendimetrazine 5 Edrisal tabs Special formula 711 tabs 6 Genegesic caps Thora Dex No. 1 tab 7 Hovizyme tabs Thora Dex No. 2 tab 8 Mazindol 9 (b) Unless listed in another schedule, any material, 10 compound, mixture, or preparation containing any quantity of the 11 following substances having a potential for abuse associated with 12 a depressant effect on the central nervous system, including 13 their salts, isomers, including optical, position, or geometric 14 isomers, and salts of the isomers if the existence of the salts, 15 isomers, and salts of isomers is possible within the specific 16 chemical designation: 17 Chlorhexadol Phencyclidine 18 Glutethimide Sulfondiethylmethane 19 Lysergic acid Sulfonethylmethane 20 Lysergix acid amide Sulfonmethane 21 Methyprylon 22 (c) Nalorphine.
    [Show full text]
  • 2019 Prohibited List
    THE WORLD ANTI-DOPING CODE INTERNATIONAL STANDARD PROHIBITED LIST JANUARY 2019 The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. This List shall come into effect on 1 January 2019 SUBSTANCES & METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) IN ACCORDANCE WITH ARTICLE 4.2.2 OF THE WORLD ANTI-DOPING CODE, ALL PROHIBITED SUBSTANCES SHALL BE CONSIDERED AS “SPECIFIED SUBSTANCES” EXCEPT SUBSTANCES IN CLASSES S1, S2, S4.4, S4.5, S6.A, AND PROHIBITED METHODS M1, M2 AND M3. PROHIBITED SUBSTANCES NON-APPROVED SUBSTANCES Mestanolone; S0 Mesterolone; Any pharmacological substance which is not Metandienone (17β-hydroxy-17α-methylandrosta-1,4-dien- addressed by any of the subsequent sections of the 3-one); List and with no current approval by any governmental Metenolone; regulatory health authority for human therapeutic use Methandriol; (e.g. drugs under pre-clinical or clinical development Methasterone (17β-hydroxy-2α,17α-dimethyl-5α- or discontinued, designer drugs, substances approved androstan-3-one); only for veterinary use) is prohibited at all times. Methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien- 3-one); ANABOLIC AGENTS Methyl-1-testosterone (17β-hydroxy-17α-methyl-5α- S1 androst-1-en-3-one); Anabolic agents are prohibited. Methylnortestosterone (17β-hydroxy-17α-methylestr-4-en- 3-one); 1. ANABOLIC ANDROGENIC STEROIDS (AAS) Methyltestosterone; a. Exogenous*
    [Show full text]